Endocyte, Inc. was a big mover last session, as the company saw its shares rise more than 11% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This stock, which remained volatile and traded within the range of $15.80–$19.95 in the past one-month time frame, witnessed a sharp increase yesterday.
The stock gained after the company announced that the U.S. FDA has accepted its Radiographic Progression Free Survival (rPFS) as an alternative primary endpoint for the VISION trial.
The company has seen no changes when it comes to estimate revision over the past few weeks, while the Zacks Consensus Estimate for the current quarter has also remained unchanged. The recent price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Endocyte currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.
Investors interested in the Medical - Drugs industry may consider Pacira Pharmaceuticals, Inc. (PCRX - Free Report) , which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Is ECYT going up? Or down? Predict to see what others think:Up or Down
5 Medical Stocks to Buy Now
Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.
New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.
Click here to see the 5 stocks >>